Ceftolozane-tazobactam in nosocomial pneumonia

Ceftolozane is a potent antimicrobial against Pseudomonas aeruginosa, including carbapenem-resistant and multidrug-resistant strains, and is also active against Enterobacteriaceae. It MIC (minimal inhibitory concentration) and MPC (mutant preventive concentration) are close together, allowing to avo...

Full description

Saved in:
Bibliographic Details
Published in:Revista española de quimioterapia 2022-04, Vol.35 Suppl 1 (Suppl1), p.35-39
Main Authors: Candel, F J, González Del Castillo, J, Julián Jiménez, A, Matesanz, M
Format: Article
Language:English
Subjects:
Adult
Cephalosporins
Cross Infection - drug therapy
Healthcare-Associated Pneumonia - drug therapy
Humans
New Antimicrobial Alternatives in the Treatment of Pneumonia
Pseudomonas Infections - drug therapy
Tazobactam - pharmacology
Tazobactam - therapeutic use
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ceftolozane is a potent antimicrobial against Pseudomonas aeruginosa, including carbapenem-resistant and multidrug-resistant strains, and is also active against Enterobacteriaceae. It MIC (minimal inhibitory concentration) and MPC (mutant preventive concentration) are close together, allowing to avoid the mutant selection window specifically in the treatment of Pseudomonas aeruginosa infection. The molecule is time-dependent and stable when reconstituted at room temperature, facilitating safe and effective dosage optimization in frail and critically ill patients. It has been shown to be non-inferior to meropenem in the treatment of nosocomial infection in the ASPECT-NP study but superior in post-hoc studies in the subgroup of patients with ventilator-associated pneumonia, without the emergence of resistance during treatment. It is FDA approved at a dose of 3 g every 8 hours in the treatment of nosocomial pneumonia (HABP/VABP) in adults.
ISSN:0214-3429
1988-9518
DOI:10.37201/req/s01.08.2022